ACLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcellx Inc (ACLX) is not a good buy for a long-term beginner investor at this time. The stock is trading near the acquisition price of $115 per share, and analysts have downgraded it to Neutral or Hold due to the finalized acquisition terms with Gilead. There is limited upside potential, and no significant trading or growth catalysts are present. Additionally, insider selling and declining financial performance further diminish its attractiveness.
The stock is in an overbought zone with an RSI of 90.056, indicating potential for a pullback. The MACD is positive but contracting, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The current price of $114.68 is near the resistance level of $115.267, which aligns with the acquisition price.
The acquisition by Gilead provides a clear exit strategy for shareholders at $115 per share, with an additional contingent value right (CVR) of $5 per share.
Insider selling has increased by 642.87% over the past month.
Analysts have downgraded the stock to Neutral or Hold due to the acquisition, limiting potential upside.
Investigations into the fairness of the Gilead transaction may create uncertainty.
Financial performance has significantly declined, with revenue dropping by 89.17% YoY in Q4 2025.
In Q4 2025, revenue dropped by 89.17% YoY to $1.65M. Net income improved slightly but remains negative at -$58.1M. EPS increased to -1, up 14.94% YoY. Gross margin remains at 100%. Overall, the financials indicate weak growth and profitability.
Analysts have downgraded the stock to Neutral or Hold, with a consensus price target of $115, aligning with the Gilead acquisition price. No competing offers are expected, and the deal is anticipated to close in Q2 2026.
